Friday 6 November 2026 Export PODD’s income statement to Excel — free account

Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.

Revenue: +19.2%
EPS: +64.1%
Free cash flow: −29.8%
Total debt: −5.19%

Quarter to September 2026, against a year earlier

146.38 9.74 −6.24%

Follow PODD

Alert me

Market cap: $10.8B
P/E: 25.2×
Fwd P/E: 24.4×
Dividend yield: —
F-score: 6/9
Altman Z: 9.09
Beneish M: −2.59
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Insulet Corporation (PODD) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Insulet Corporation (PODD) trades at a price to free cash flow of 46.4×. Over the past ten years it has ranged from 0.0× (December 2023) to 2,511× (December 2015); the current reading is higher than 79% of that period. That is above the Medical Devices industry median of 28.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/PODD/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Insulet Corporation price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/PODD/metrics/price-to-free-cash-flow">Insulet Corporation (PODD) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	57.1×	(7.48%)
FY2024	61.8×	(84.54%)
FY2023	400×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	0.0×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	Price to free cash flow	Change
Sep 2026	39.0×	(1.77%)
Jun 2026	39.7×	4.90%
Mar 2026	37.9×	(33.73%)
Dec 2025	57.1×	7.19%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 2,511×

Ten-year median 0.0×

Current reading's percentile 79

Company	Price to free cash flow
SNN Smith & Nephew SNATS, Inc. compare	7.1×
GMED Globus Medical, Inc. compare	14.5×
BIO Bio-Rad Laboratories, Inc. compare	30.0×
BIO.B Bio-Rad Laboratories, Inc. compare	30.7×
BRKR Bruker Corporation compare	32.9×
PODD Insulet Corporation	46.4×
PEN Penumbra, Inc. compare	63.1×
TXG 10x Genomics compare	63.3×
GKOS Glaukos Corporation compare	360×
Medical Devices industry median	28.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Insulet Corporation (PODD) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on PODD

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on PODD

Stockrow Weekly